Beijing Shenogen Biomedical Co., Ltd   Report issue

For profit Phase 3
Founded: Beijing China (2010)

Organization Overview

First Clinical Trial
2010
NCT01278810
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Beijing Shenogen Biomedical Co., Ltd

Active Ingredients

Drugs in Phase 3 Trials (3)

Epimedium (6 trials)

huachansu pian (2 trials)

sorafenib (nexavar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 3